Literature DB >> 30554008

Phospholipase A2 products predict the hematopoietic support capacity of horse serum.

Timo Ditz1, Lydia Schnapka-Hille2, Nicole Noack2, Juliane Dorow3, Uta Ceglarek3, Dietger Niederwieser2, Jürgen Schiller4, Beate Fuchs5, Michael Cross2.   

Abstract

Horse serum is commonly used as an additive to support the maintenance of hematopoietic progenitor cells in culture. However, the wide variability in the performance of different lots calls for parallel testing of multiple batches over extended periods of culture. Identification of the serum components that determine hematopoietic support would therefore save considerable time and effort and would help to standardize culture procedures. We report here that the ability of horse serum to support the self-renewal of multipotent murine hematopoietic progenitor FDCP-Mix cells is correlated to the concentration of specific fatty acid products of phospholipase A2 and more closely to the spectrum of eicosanoids generated by their further processing through cyclooxygenase and lipoxygenase pathways. Supportive sera have low levels of lysophosphatidylcholine and inflammatory eicosanoids. This links known markers of inflammation, infection and platelet activation to the ability of serum to maintain progenitor cells in an undifferentiated state, providing a means for prospective identification of suitable sera as well as quality control of the production process.
Copyright © 2018 International Society of Differentiation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell culture; Eicosanoids; Hematopoiesis; Horse serum; Lysophosphatidylcholine

Mesh:

Substances:

Year:  2018        PMID: 30554008     DOI: 10.1016/j.diff.2018.12.002

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  1 in total

1.  Higher percentage of horse serum in culture media blocks attachment of PC12 cells.

Authors:  Jennifer L Meth; Alan R Schoenfeld
Journal:  Biotechniques       Date:  2019-10-17       Impact factor: 1.993

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.